keyword
MENU ▼
Read by QxMD icon Read
search

Mesothelioma, lung cancer,

keyword
https://www.readbyqxmd.com/read/28634559/malignant-pleural-mesothelioma-with-marked-lymphatic-involvement-a-report-of-two-autopsy-cases
#1
Reiko Ideguchi, Kazuto Ashizawa, Saori Akashi, Michiko Shindo, Kazunori Minami, Toshio Fukuda, Junji Irie, Minoru Fukuda, Masataka Uetani
We herein report two cases of malignant pleural mesothelioma with marked lymphangiosis. The patients included a 68-year-old man and a 67-year-old man who both had a history of exposure to asbestos. Computed tomography (CT) on admission showed pleural effusion with pleural thickening. In both cases, a histopathological examination of the pleura confirmed the diagnosis of epithelioid malignant mesothelioma. They received chemotherapy, but the treatment was only palliative. The chest CT assessments during admission revealed marked pleural effusion and mediastinal lymphadenopathy...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28598889/survival-of-solid-cancer-patients-in-france-1989-2013-a-population-based-study
#2
Anne Cowppli-Bony, Zoé Uhry, Laurent Remontet, Nicolas Voirin, Anne-Valérie Guizard, Brigitte Trétarre, Anne-Marie Bouvier, Marc Colonna, Nadine Bossard, Anne-Sophie Woronoff, Pascale Grosclaude
This study provides updates of net survival (NS) estimates at 5, 10, and 15 years as well as survival trends for 35 solid cancers in France using data from 19 population-based cancer registries. The study considered all cases of solid cancer diagnosed between 1989 and 2010 in patients older than 15 years of age who were actively followed up until 30 June 2013. NS was estimated using the Pohar-Perme method. The age-standardized NS used the international cancer survival standard weights. The 5-year age-standardized NSs ranged from 4% (pleural mesothelioma) to 93% (prostate) in men and from 10% (pancreas) to 97% (thyroid) in women...
June 8, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28593073/cancer-incidence-in-asbestos-exposed-workers-an-update-on-four-finnish-cohorts
#3
Pia Nynäs, Eero Pukkala, Harri Vainio, Panu Oksa
BACKGROUND: We assessed the cancer risks of four different Finnish asbestos-exposed cohorts. We also explored if the cohorts with varying profiles of asbestos exposure exhibited varying relative risks of cancer. METHODS: The incident cancer cases for the asbestos-exposed worker cohorts were updated to the end of 2012 using the files of the Finnish Cancer Registry. The previously formed cohorts consisted of asbestos mine workers, asbestosis patients, asbestos sprayers, and workers who had taken part in a screening study based on asbestos exposure at work...
June 2017: Safety and Health At Work
https://www.readbyqxmd.com/read/28590338/surgery-as-part-of-radical-treatment-for-malignant-pleural-mesothelioma
#4
David A Waller, Sara Tenconi
PURPOSE OF REVIEW: To review the latest developments in surgery for malignant pleural mesothelioma both in patient selection, surgical technique, and strategy. RECENT FINDINGS: The International Association for the Study of Lung Cancer mesothelioma staging project has produced data to inform the 8th tumour node metastasis revision. The difficulty in clinical N staging and clinical T staging are highlighted and the importance of tumour volume is recognized. New imaging techniques can be utilized to assess tumour volume...
July 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/28579481/scientific-advances-in-thoracic-oncology-2016
#5
REVIEW
Ross A Soo, Emily Ca Stone, K Michael Cummings, James R Jett, John K Field, Harry Jm Groen, James L Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Dacic, Ramon Rami-Porta, Frank C Detterbeck, Eric Lim, Hisao Asamura, Jessica Donington, Heather A Wakelee, Yi Long Wu, Kristin Higgins, Suresh Senan, Benjamin Solomon, Dong-Wan Kim, Melissa Johnson, James Ch Yang, Lecia V Sequist, Alice T Shaw, Myung-Ju Ahn, Daniel B Costa, Jyoti D Patel, Leora Horn, Scott Gettinger, Solange Peters, Murry W Wynes, Corinne Faivre-Finn, Charles M Rudin, Anne Tsao, Paul Baas, Ronan J Kelly, Natasha B Leighl, Giorgio V Scagliotti, David R Gandara, Fred R Hirsch, David R Spigel
Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The IASLC and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for non-small cell lung cancer, small cell lung cancer, and mesothelioma...
May 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28545532/cytotoxicity-of-the-methanol-extracts-of-elephantopus-mollis-kalanchoe-crenata-and-4-other-cameroonian-medicinal-plants-towards-human-carcinoma-cells
#6
Victor Kuete, Fabrice W Fokou, Oğuzhan Karaosmanoğlu, Veronique P Beng, Hülya Sivas
BACKGROUND: Cancer still constitutes one of the major health concerns globally, causing serious threats on patients, their families, and the healthcare system. METHODS: In this study, the cytotoxicity of the methanol extract of Elephantopus mollis whole plant (EMW), Enantia chlorantha bark (ECB), Kalanchoe crenata leaves (KCL), Lophira alata bark (LAB), Millettia macrophylla leaves (MML) and Phragmanthera capitata leaves (PCL) towards five human solid cancer cell lines and normal CRL2120 fibroblasts, was evaluated...
May 25, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28537896/5t4-oncofoetal-glycoprotein-an-old-target-for-a-novel-prostate-cancer-immunotherapy
#7
Federica Cappuccini, Emily Pollock, Stephen Stribbling, Adrian V S Hill, Irina Redchenko
The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Vaccination-induced immune responses were strong, durable and attributable primarily to CD8+ T cells...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28536345/viroimmunotherapy-of-thoracic-cancers
#8
REVIEW
Alexander S Dash, Manish R Patel
Thoracic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and malignant pleural mesothelioma (MM), cause the highest rate of cancer mortality worldwide. Most of these deaths are as a result of NSCLC; however, prognoses for the other two diseases remain as some of the poorest of any cancers. Recent advances in immunotherapy, specifically immune checkpoint inhibitors, have begun to help a small population of patients with advanced lung cancer. People who respond to these immune therapies generally have a durable response and many see dramatic decreases in their disease...
January 4, 2017: Biomedicines
https://www.readbyqxmd.com/read/28525370/mathematical-modelling-for-phase-i-cancer-trials-a-study-of-metronomic-vinorelbine-for-advanced-non-small-cell-lung-cancer-nsclc-and-mesothelioma-patients
#9
Fabrice Barlesi, Diane-Charlotte Imbs, Pascale Tomasini, Laurent Greillier, Melissa Galloux, Albane Testot-Ferry, Mélanie Garcia, Xavier Elharrar, Annick Pelletier, Nicolas André, Céline Mascaux, Bruno Lacarelle, Raouf El Cheikh, Raphaël Serre, Joseph Ciccolini, Dominique Barbolosi
INTRODUCTION: Using mathematical modelling allows to select a treatment's regimen across infinite possibilities. Here, we report the phase I assessment of a new schedule for metronomic vinorelbine in treating refractory advanced NSCLC and mesothelioma patients. RESULTS: Overall, 13 patients were screened and 12 were treated (50% male, median age: 68yrs), including 9 NSCLC patients. All patients received at least one week (3 doses) of treatment. At data cut-off, the median length of treatment was 6...
May 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28502785/car-t-cell-therapy-for-lung-cancer-and-malignant-pleural-mesothelioma
#10
REVIEW
Masha Zeltsman, Jordan Dozier, Erin McGee, Daniel Ngai, Prasad S Adusumilli
Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. One such approach being investigated is administration of tumor antigen-targeted T cells with transduction of a chimeric antigen receptor (CAR)...
April 26, 2017: Translational Research: the Journal of Laboratory and Clinical Medicine
https://www.readbyqxmd.com/read/28491851/pemetrexed-induced-acute-kidney-failure-following-irreversible-renal-damage-two-case-reports-and-literature-review
#11
Tito Zattera, Francesco Londrino, Matteo Trezzi, Roberto Palumbo, Antonio Granata, Paola Tatangelo, Valentina Corbani, Valeria Falqui, Nadia Chiappini, Lisa Mathiasen, Marco Cavallini, Davide Rolla
BACKGROUND: Pemetrexed (PEM) is a new-generation multitargeted antifolate agent with a demonstrated broad-spectrum activity in several types of human cancers, including non-small cell lung cancer (NSCLC) and mesothelioma. Major side effects include dose-limiting hematologic toxicities. PEM nephrotoxicity is well known; however, its frequency is considered to be low. CASE PRESENTATION: Here we report two cases of acute kidney injury (AKI) related to PEM administration (500 mg/m2) in patients with NSCLC...
March 2017: Journal of Nephropathology
https://www.readbyqxmd.com/read/28490663/quantitative-estimated-exposure-to-vinyl-chloride-and-risk-of-angiosarcoma-of-the-liver-and-hepatocellular-cancer-in-the-us-industry-wide-vinyl-chloride-cohort-mortality-update-through-2013
#12
Kenneth A Mundt, Linda D Dell, Lori Crawford, Alexa E Gallagher
OBJECTIVE: To evaluate mortality risks of angiosarcoma of the liver (ASL), primary hepatocellular carcinoma (HCC) and other cancers among 9951 men employed between 1942 and 1972 at 35 US vinyl chloride (VC) or polyvinyl chloride plants followed for mortality through 31 December 2013. METHODS: SMR and time-dependent Cox proportional hazards analyses were used to evaluate mortality risks by cumulative VC exposure. RESULTS: Liver cancer mortality was elevated (SMR=2...
May 10, 2017: Occupational and Environmental Medicine
https://www.readbyqxmd.com/read/28485001/successful-lung-sparing-resection-of-synchronous-pleural-mesothelioma-and-contralateral-lung-cancer
#13
Naoko Imanishi, Yusuke Nabe, Masaru Takenaka, Yasuhiro Chikaishi, Koji Kuroda, Hirotsugu Noguchi, Kazuhiro Yatera, Fumihiro Tanaka
BACKGROUND: Malignant pleural mesothelioma (MPM) is an uncommon malignant tumor, and its synchronous occurrence with primary lung cancer is extremely rare. Here, we report the first surgical case of synchronous MPM and contralateral lung adenocarcinoma. Extrapleural pneumonectomy (EPP) combined with surgery for contralateral lung cancer may not be tolerated, and a lung-sparing procedure including pleurectomy/decortication (P/D) can be an alternative to achieve complete resection. CASE PRESENTATION: A 69-year-old male with right MPM and lung adenocarcinoma in the left upper lobe presented...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28449331/mir-130a-as-a-diagnostic-marker-to-differentiate-malignant-mesothelioma-from-lung-adenocarcinoma-in-pleural-effusion-cytology
#14
Rocco Cappellesso, Marco Galasso, Lorenzo Nicolè, Paolo Dabrilli, Stefano Volinia, Ambrogio Fassina
BACKGROUND: Malignant pleural mesothelioma is a rare tumor with a dismal prognosis, usually presenting with recurrent effusions. However, the majority of malignant pleural effusions are due to lung adenocarcinoma (AdC). The distinction between these tumors has considerable therapeutic and medicolegal implications and can be very challenging both histologically and cytologically. Appropriate immunohistochemistry (IHC) is required to support the diagnosis. MicroRNA (miRNA) expression analysis could be a viable diagnostic tool for distinguishing between these tumors...
April 27, 2017: Cancer
https://www.readbyqxmd.com/read/28434399/the-next-generation-of-immunotherapy-keeping-lung-cancer-in-check
#15
REVIEW
Ashwin Somasundaram, Timothy F Burns
Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experienced a significant improvement in mortality. Lung cancer has been shown to be immunogenic and responsive to checkpoint blockade therapy. Checkpoint signals such as CTLA-4 and PD-1/PD-L1 dampen T cell activation and allow tumors to escape the adaptive immune response. Response rates in patients with pretreated, advanced NSCLC were much higher and more durable with PD-1 blockade therapy compared to standard-of-care, cytotoxic chemotherapy...
April 24, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28428185/investments-in-cancer-research-awarded-to-uk-institutions-and-the-global-burden-of-cancer-2000-2013-a-systematic-analysis
#16
Mahiben Maruthappu, Michael G Head, Charlie D Zhou, Barnabas J Gilbert, Majd A El-Harasis, Rosalind Raine, Joseph R Fitchett, Rifat Atun
OBJECTIVES: To systematically categorise cancer research investment awarded to United Kingdom (UK) institutions in the period 2000-2013 and to estimate research investment relative to disease burden as measured by mortality, disability-adjusted life years (DALYs) and years lived with disability (YLDs). DESIGN: Systematic analysis of all open-access data. SETTING AND PARTICIPANTS: Public and philanthropic funding to all UK cancer research institutions, 2000-2013...
April 20, 2017: BMJ Open
https://www.readbyqxmd.com/read/28410823/the-case-for-performing-pleural-biopsies-for-the-aetiological-diagnosis-of-exudates-yes
#17
F Rodriguez-Panadero
Pleural biopsies are especially indicated in the following circumstances: a) inconclusive pleural fluid analysis and negative sputum study, if adenosine deaminase (ADA) levels are unavailable; b) suspected multi-resistant tuberculosis; c) a need for differentiating tuberculous pleurisy (if it progresses with neutrophilia) and complicated parapneumonic effusion; d) malignant pleural effusion coexisting with very high ADA levels; e) effusion coexisting with lung cancer and negative pleural cytology; f) suspected mesothelioma; and g) need for implementing re-treatment for patients with relapse after chemotherapy...
April 12, 2017: Revista Clínica Española
https://www.readbyqxmd.com/read/28403901/cd44-and-its-ligand-hyaluronan-as-potential-biomarkers-in-malignant-pleural-mesothelioma-evidence-and-perspectives
#18
REVIEW
Lourdes Cortes-Dericks, Ralph Alexander Schmid
Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient serum are reasonable options to provide a faster and noninvasive diagnostic approach. As yet, the current biomarkers for MPM lack specificity and sensitivity to discriminate this neoplasm from other lung tumors...
April 12, 2017: Respiratory Research
https://www.readbyqxmd.com/read/28395242/analysis-of-fibulin-3-after-exposure-to-asbestos-like-fibers
#19
Venerando Rapisarda, Rosario Caltabiano, Giuseppe Musumeci, Paola Castrogiovanni, Margherita Ferrante, Caterina Ledda, Claudia Lombardo, Adriana Carol Eleonora Graziano, Venera Cardile, Carla Loreto
A significantly increased incidence of malignant mesothelioma in Biancavilla (Sicily, Italy) has been ascribed to exposure to fluoro-edenite, a fibrous amphibole extracted from a local stone quarry. Fibulin-3 is a highly conserved glycoprotein proposed as a biomarker for malignant mesothelioma that belongs to the family of extracellular matrix proteins. Previous studies demonstrated high Fibulin-3 plasma levels in workers with pleural plaques exposed to fluoro-edenite. Therefore, in order to gain insight into the biomolecular mechanisms of fluoro-edenite toxicity, we performed the analysis of Fibulin-3 expression by immunohistochemistry in the lung samples derived from sheep belonging to the area of Biancavilla...
July 2017: Environmental Research
https://www.readbyqxmd.com/read/28388291/phase-1-dose-escalation-study-of-pegylated-arginine-deiminase-cisplatin-and-pemetrexed-in-patients-with-argininosuccinate-synthetase-1-deficient-thoracic-cancers
#20
Emma Beddowes, James Spicer, Pui Ying Chan, Ramsay Khadeir, Javier Garcia Corbacho, Dimitra Repana, Jeremy P Steele, Peter Schmid, Teresa Szyszko, Gary Cook, Monica Diaz, Xiaoxing Feng, Amanda Johnston, Jim Thomson, Michael Sheaff, Bor-Wen Wu, John Bomalaski, Simon Pacey, Peter W Szlosarek
Purpose Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant pleural mesothelioma (MPM) or non-small-cell lung cancer (NSCLC). Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naïve patients (five MPM, four NSCLC) received weekly ADI-PEG 20 doses of 18 mg/m(2), 27 mg/m(2), or 36 mg/m(2), together with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) which were given every three weeks (maximum of six cycles)...
June 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
40554
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"